Cargando…

Large dosage Huanglian (Rhizoma Coptidis) for T2DM: A protocol of systematic review and meta-analysis of randomized clinical trials

INTRODUCTION: Type 2 diabetes mellitus(T2DM) is a widespread attention of the world's major health problems. The international diabetes federation (IDF) has released the “global overview of diabetes (ninth edition)”. By 2019. It can lead to complications and even death. Among them, the use of R...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lizhen, Huang, Xiaoying, Yue, Rensong, Yang, Hongjing, Zhang, Xinyue, Tian, Yuan, Ding, Ning, Zhou, Linyue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505349/
https://www.ncbi.nlm.nih.gov/pubmed/32957328
http://dx.doi.org/10.1097/MD.0000000000022066
_version_ 1783584792103616512
author Wang, Lizhen
Huang, Xiaoying
Yue, Rensong
Yang, Hongjing
Zhang, Xinyue
Tian, Yuan
Ding, Ning
Zhou, Linyue
author_facet Wang, Lizhen
Huang, Xiaoying
Yue, Rensong
Yang, Hongjing
Zhang, Xinyue
Tian, Yuan
Ding, Ning
Zhou, Linyue
author_sort Wang, Lizhen
collection PubMed
description INTRODUCTION: Type 2 diabetes mellitus(T2DM) is a widespread attention of the world's major health problems. The international diabetes federation (IDF) has released the “global overview of diabetes (ninth edition)”. By 2019. It can lead to complications and even death. Among them, the use of Rhizoma Coptidis (Huanglian) at large dose has also been proved to be effective in clinical practice. However, due to the lack of evidence, there is no specific method or suggestion, so it is necessary to carry out systematic evaluation on coptis coptis and provide effective evidence for further research. METHODS AND ANALYSIS: We will search the following electronic databases from their inception to May 2020: Electronic database includes PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure. Primary outcomes:fasting blood glucose and glycosylated haemoglobin (A1c). Secondary outcomes: plasma insulin,blood lipid profile,adverse events,and cost associated with the intervention and hospital visit. Data will be extracted by 2 researchers independently, risk of bias of the meta-analysis will be evaluated based on the Cochrane Handbook for Systematic Reviews of Interventions. All data analysis will be conducted by data statistics software Review Manager V.5.3. and Stata V.12.0. RESULTS: The results of this study will systematically evaluate the effectiveness and safety of large dose of Huanglian intervention for people with T2DM. CONCLUSION: The systematic review of this study will summarize the current published evidence of large dose of Huanglian for the treatment of T2DM, which can further guide the promotion and application of it. ETHICS AND DISSEMINATION: This study is a systematic review, the outcomes are based on the published evidence, so examination and agreement by the ethics committee are not required in this study. We intend to publish the study results in a journal or conference presentations. Open Science Framework(OSF)registration number: July 21, 2020. https://osf.io/w7bj6
format Online
Article
Text
id pubmed-7505349
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-75053492020-09-24 Large dosage Huanglian (Rhizoma Coptidis) for T2DM: A protocol of systematic review and meta-analysis of randomized clinical trials Wang, Lizhen Huang, Xiaoying Yue, Rensong Yang, Hongjing Zhang, Xinyue Tian, Yuan Ding, Ning Zhou, Linyue Medicine (Baltimore) 4300 INTRODUCTION: Type 2 diabetes mellitus(T2DM) is a widespread attention of the world's major health problems. The international diabetes federation (IDF) has released the “global overview of diabetes (ninth edition)”. By 2019. It can lead to complications and even death. Among them, the use of Rhizoma Coptidis (Huanglian) at large dose has also been proved to be effective in clinical practice. However, due to the lack of evidence, there is no specific method or suggestion, so it is necessary to carry out systematic evaluation on coptis coptis and provide effective evidence for further research. METHODS AND ANALYSIS: We will search the following electronic databases from their inception to May 2020: Electronic database includes PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure. Primary outcomes:fasting blood glucose and glycosylated haemoglobin (A1c). Secondary outcomes: plasma insulin,blood lipid profile,adverse events,and cost associated with the intervention and hospital visit. Data will be extracted by 2 researchers independently, risk of bias of the meta-analysis will be evaluated based on the Cochrane Handbook for Systematic Reviews of Interventions. All data analysis will be conducted by data statistics software Review Manager V.5.3. and Stata V.12.0. RESULTS: The results of this study will systematically evaluate the effectiveness and safety of large dose of Huanglian intervention for people with T2DM. CONCLUSION: The systematic review of this study will summarize the current published evidence of large dose of Huanglian for the treatment of T2DM, which can further guide the promotion and application of it. ETHICS AND DISSEMINATION: This study is a systematic review, the outcomes are based on the published evidence, so examination and agreement by the ethics committee are not required in this study. We intend to publish the study results in a journal or conference presentations. Open Science Framework(OSF)registration number: July 21, 2020. https://osf.io/w7bj6 Lippincott Williams & Wilkins 2020-09-18 /pmc/articles/PMC7505349/ /pubmed/32957328 http://dx.doi.org/10.1097/MD.0000000000022066 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/)
spellingShingle 4300
Wang, Lizhen
Huang, Xiaoying
Yue, Rensong
Yang, Hongjing
Zhang, Xinyue
Tian, Yuan
Ding, Ning
Zhou, Linyue
Large dosage Huanglian (Rhizoma Coptidis) for T2DM: A protocol of systematic review and meta-analysis of randomized clinical trials
title Large dosage Huanglian (Rhizoma Coptidis) for T2DM: A protocol of systematic review and meta-analysis of randomized clinical trials
title_full Large dosage Huanglian (Rhizoma Coptidis) for T2DM: A protocol of systematic review and meta-analysis of randomized clinical trials
title_fullStr Large dosage Huanglian (Rhizoma Coptidis) for T2DM: A protocol of systematic review and meta-analysis of randomized clinical trials
title_full_unstemmed Large dosage Huanglian (Rhizoma Coptidis) for T2DM: A protocol of systematic review and meta-analysis of randomized clinical trials
title_short Large dosage Huanglian (Rhizoma Coptidis) for T2DM: A protocol of systematic review and meta-analysis of randomized clinical trials
title_sort large dosage huanglian (rhizoma coptidis) for t2dm: a protocol of systematic review and meta-analysis of randomized clinical trials
topic 4300
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505349/
https://www.ncbi.nlm.nih.gov/pubmed/32957328
http://dx.doi.org/10.1097/MD.0000000000022066
work_keys_str_mv AT wanglizhen largedosagehuanglianrhizomacoptidisfort2dmaprotocolofsystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT huangxiaoying largedosagehuanglianrhizomacoptidisfort2dmaprotocolofsystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT yuerensong largedosagehuanglianrhizomacoptidisfort2dmaprotocolofsystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT yanghongjing largedosagehuanglianrhizomacoptidisfort2dmaprotocolofsystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT zhangxinyue largedosagehuanglianrhizomacoptidisfort2dmaprotocolofsystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT tianyuan largedosagehuanglianrhizomacoptidisfort2dmaprotocolofsystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT dingning largedosagehuanglianrhizomacoptidisfort2dmaprotocolofsystematicreviewandmetaanalysisofrandomizedclinicaltrials
AT zhoulinyue largedosagehuanglianrhizomacoptidisfort2dmaprotocolofsystematicreviewandmetaanalysisofrandomizedclinicaltrials